News & Updates

Treatment with tirzepatide, compared with placebo, results in significant reductions in body weight, waist circumference, and waist-to-height ratio (WHtR) among women with obesity or overweight and without type 2 diabetes (T2D), regardless of reproductive stage.

In the protocol-specified final overall survival (OS) analysis of the phase III MARIPOSA trial, treatment with amivantamab plus lazertinib significantly reduced the risk of death in individuals with previously untreated EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).

First-line treatment with chemotherapy plus pembrolizumab followed by maintenance with pembrolizumab plus olaparib, with or without bevacizumab, appears to prolong progression-free survival (PFS) in advanced epithelial ovarian cancer without BRCA 1/2 mutations, according to data from the phase III ENGOT-ov43/GOG-3036/KEYLYNK-001 trial.

Treatment with monoclonal antibodies (mAbs) among COVID-19 patients is associated with a higher risk of hepatotoxicity and neutropenia when compared with standard of care (SoC) or placebo, reports a study.